After five years of Dupixent’s reign for Sanofi, the U.K.'s medicines regulatory agency is warning about the risks of ocular side effects. In a Tuesday update from the U.K.'s Medicines and Healthcare ...
Aslan Pharmaceuticals is trying to come for Dupixent’s billion-dollar crown in atopic dermatitis, but with mid-stage data showing a more comparable than superior profile, the company hopes less ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback